Neomycin Sulfate

Pseudomonas Infections, Otitis Externa, Klebsiella + 15 more

Treatment

9 FDA approvals

20 Active Studies for Neomycin Sulfate

Treatment for

Pseudomonas Infections

What is Neomycin Sulfate

Polymyxin B

The Generic name of this drug

Treatment Summary

Neomycin is a type of antibiotic used to treat bacterial infections. It is made from the metabolic products of a certain type of bacteria. Neomycin is a complex made up of three different components, with neomycin B and C being the active ingredients. It is mainly used to treat bacterial infections in the ear, eye, and skin. Neomycin sulfate is the most common form of the drug and is available as a solution, otic suspension, and ophthalmic preparation. It is also available in over-the-counter topical products.

Polysporin

is the brand name

image of different drug pills on a surface

Neomycin Sulfate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Polysporin

Polymyxin B

1951

279

Approved as Treatment by the FDA

Polymyxin B, commonly known as Polysporin, is approved by the FDA for 9 uses like Meningitis, Bacterial and Conjunctivitis .

Meningitis, Bacterial

Conjunctivitis

Used to treat Ocular Inflammation in combination with Dexamethasone

Ocular Inflammation

Used to treat Ocular Inflammation in combination with Dexamethasone

Bacterial Infections

Urinary Tract Infections

ocular bacterial infections

Used to treat ocular bacterial infections in combination with Bacitracin

Bacteremia caused by Enterobacter aerogenes

Pseudomonas Infections

Urinary Tract Infection (UTI)

Effectiveness

How Neomycin Sulfate Affects Patients

Neomycin works by blocking the production of proteins in bacteria, which stops them from growing and surviving. This effect can last for up to 72 hours after taking the drug. Additionally, neomycin helps reduce the number of bacteria in the colon that produce ammonia, which can help improve neurological symptoms in those with hepatic coma. Neomycin works on both gram-positive and gram-negative bacteria, including the common species of E. coli and Klebsiella-Enterobacter group. However, some strains of E. coli, Klebsiella, and Proteus spp. have developed resistance to neomycin

How Neomycin Sulfate works in the body

Neomycin is an antibiotic that works by preventing bacteria from making proteins, which stops them from multiplying. It does this by binding to the bacterial ribosomes, which are responsible for making proteins, and blocking them from working correctly.

When to interrupt dosage

The proposed dose of Neomycin Sulfate is contingent upon the diagnosed disorder, such as Itching arising from Infection, Secondarily Infected Eczema and Communicable Diseases. Dosage can be found in the table below, contingent upon the technique of delivery (e.g. Suspension - Auricular (otic) or Topical).

Condition

Dosage

Administration

Urinary tract infection

, 100000.0 [USP'U]/mL, 5.0 [USP'U]/mg, 10.0 [USP'U]/mg, 10.0 [iU]/mg, 5.0 [iU]/mg, 200000.0 [USP'U]/mL, 10000.0 [USP'U]/mL, 1.0 [USP'U]/mg, 10000.0 units/mL, 10000.0 mL/mL, 10.0 mg/mg, 10000.0 mg/mL, 500000.0 [iU], 500000.0 [USP'U], 10.0 units/mg, 5000.0 [USP'U], 5.0 units/mg, 5.3228 [iU]/mg, 10000.0 [iU]/mL, 200000.0 [iU]/mL, 0.5 units/mg, 0.0052 mg/mg, 1.0 [iU]/mg, 16250.0 units/mL, 1500.0 units, 50.0 [iU]/mg, 0.01 mg/mg, 0.1 [USP'U]/mg, 10000.0 mg/mg, 50.0 mg, 500000.0 units, 0.77 mg/mL, 5000.0 units/mL, 15.0 [USP'U]/mg, 0.006 mg/mg, 6.0 units/mg, 6000.0 units/mL, 200000.0 units/mL, 1.0 units/mg

Ophthalmic, Solution / drops - Ophthalmic, Topical, Ointment - Topical, , Cream - Topical, Ointment - Ophthalmic, Irrigant - Irrigation, Irrigation, Suspension / drops - Auricular (otic), Auricular (otic), Solution / drops - Auricular (otic), Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Solution - Ophthalmic, Intramuscular; Intrathecal; Intravenous; Ophthalmic, Injection, powder, lyophilized, for solution - Intramuscular; Intrathecal; Intravenous; Ophthalmic, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Solution - Irrigation, Stick - Topical, Suspension - Auricular (otic), Powder - Topical, Solution - Auricular (otic), Liquid - Auricular (otic), Cream, Kit, Injection, solution - Intramuscular; Intrathecal; Intravenous; Ophthalmic, Intramuscular; Intrathecal; Intravenous, Intramuscular; Intrathecal; Intravenous; Respiratory (inhalation); Topical, Ointment, Kit - Topical, Liquid - Ophthalmic, Solution / drops, Solution, Suspension, Suspension / drops, Lozenge, Gel - Topical, Liquid, Buccal, Auricular (otic); Ophthalmic, Ointment - Ophthalmic; Topical, Lozenge - Oral, Lozenge - Buccal, Oral, Injection - Intramuscular; Intrathecal; Intravenous, Solution / drops - Auricular (otic); Ophthalmic, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, for solution - Intramuscular; Intrathecal; Intravenous; Ophthalmic, Ointment; Swab - Topical, Intramuscular; Intravenous, Powder, Injection, Injection, powder, for solution, Solution - Auricular (otic); Ophthalmic, Stick, Ophthalmic; Topical, Injection, solution, Powder, for solution - Intramuscular; Intrathecal; Intravenous; Respiratory (inhalation); Topical, Kit - Oral; Topical, Oral; Topical, Gel, Swab - Topical, Ointment; Swab, Suspension - Topical, Powder, for solution - Intramuscular; Intrathecal; Intravenous; Ophthalmic, Swab, Irrigant, Liquid - Auricular (otic); Ophthalmic, Solution - Urethral, Urethral, Injection, powder, lyophilized, for solution - Intramuscular; Intrathecal; Intravenous, Kit - Irrigation; Ophthalmic; Respiratory (inhalation); Topical, Irrigation; Ophthalmic; Respiratory (inhalation); Topical, Kit - Irrigation; Ophthalmic; Topical, Irrigation; Ophthalmic; Topical, Kit - Ophthalmic, Electro-osmosis, Kit - Ophthalmic; Topical, Kit - Electro-osmosis, Kit - Ophthalmic; Respiratory (inhalation); Topical, Ophthalmic; Oral; Respiratory (inhalation); Topical, Kit - Ophthalmic; Oral; Respiratory (inhalation); Topical, Ophthalmic; Respiratory (inhalation); Topical, Kit - Irrigation; Ophthalmic; Oral; Respiratory (inhalation); Topical, Kit - Irrigation; Oral; Respiratory (inhalation); Topical, Irrigation; Oral; Respiratory (inhalation); Topical, Irrigation; Ophthalmic; Oral; Respiratory (inhalation); Topical, Ophthalmic; Oral; Topical, Kit - Ophthalmic; Oral; Topical, Kit - Respiratory (inhalation); Topical, Respiratory (inhalation); Topical, Oral; Respiratory (inhalation); Topical, Kit - Oral; Respiratory (inhalation); Topical, Suspension / drops - Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated

Otitis

Pseudomonas Infections

Klebsiella

Otorrhoea

Urinary Tract Infections

Conjunctivitis, Bacterial

Conjunctivitis

Bacteria

Meningitis, Bacterial

Bacteremia caused by Enterobacter aerogenes

Communicable Diseases

Otitis Externa

Ear Inflammation

Conjunctivitis

Meningitis caused by Haemophilus influenzae

ocular bacterial infections

Urinary Tract Infection (UTI)

Warnings

Neomycin Sulfate Contraindications

Condition

Risk Level

Notes

conjunctiva

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Neomycin Sulfate.

Common Neomycin Sulfate Drug Interactions

Drug Name

Risk Level

Description

Vibrio cholerae CVD 103-HgR strain live antigen

Major

The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Polymyxin B.

Naxitamab

Minor

Polymyxin B may increase the neurotoxic activities of Naxitamab.

Typhoid vaccine

Minor

The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Polymyxin B.

(R)-warfarin

Moderate

The risk or severity of bleeding can be increased when Polymyxin B is combined with (R)-warfarin.

(S)-Warfarin

Moderate

The risk or severity of bleeding can be increased when Polymyxin B is combined with (S)-Warfarin.

Neomycin Sulfate Toxicity & Overdose Risk

Neomycin sulfate has a low toxicity in mice, with an oral LD50 greater than 8 g/kg, a subcutaneous LD50 of 200 mg/kg in rats and 190 mg/kg in mice, and an intraperitoneal LD50 of 305 mg/kg in mice. It is unlikely to cause an overdose through oral ingestion, since it is poorly absorbed. However, it can still cause serious side effects such as nerve damage, hearing loss, and kidney damage when administered over time, especially in those with kidney impairment. Pregnant women should not take neomycin as it may cause total irreversible bilateral congen

image of a doctor in a lab doing drug, clinical research

Neomycin Sulfate Novel Uses: Which Conditions Have a Clinical Trial Featuring Neomycin Sulfate?

405 active clinical trials are currently underway to assess the potential of Neomycin Sulfate in alleviating Inflammation, Atopic Dermatitis and related skin conditions.

Condition

Clinical Trials

Trial Phases

Otitis

3 Actively Recruiting

Not Applicable

Urinary Tract Infections

7 Actively Recruiting

Not Applicable, Phase 4

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

Bacteria

2 Actively Recruiting

Phase 3

Communicable Diseases

0 Actively Recruiting

Meningitis, Bacterial

0 Actively Recruiting

Pseudomonas Infections

0 Actively Recruiting

Otitis Externa

0 Actively Recruiting

ocular bacterial infections

0 Actively Recruiting

Urinary tract infection

0 Actively Recruiting

Conjunctivitis, Bacterial

0 Actively Recruiting

Conjunctivitis

0 Actively Recruiting

Klebsiella

0 Actively Recruiting

Ear Inflammation

0 Actively Recruiting

Meningitis caused by Haemophilus influenzae

0 Actively Recruiting

Conjunctivitis

0 Actively Recruiting

Otorrhoea

0 Actively Recruiting

Bacteremia caused by Enterobacter aerogenes

0 Actively Recruiting

Patient Q&A Section about neomycin sulfate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is neomycin sulfate good for skin?

"Neomycin Sulphate Cream is effective against a variety of skin infections, including boils, impetigo, and infected hair follicles. It can also be used to treat infections in small cuts or wounds on the skin."

Answered by AI

What are the side effects of neomycin sulfate?

"If you experience any of the following symptoms, please contact a doctor as soon as possible: hearing loss, clumsiness, difficulty breathing, drowsiness, decreased frequency of urination or amount of urine, increased amount of gas, increased thirst, light-colored, frothy, fatty-appearing stools."

Answered by AI

What is neomycin sulfate used for?

"Neomycin is an antibiotic that is used to treat or prevent skin infections that are caused by bacteria. It is not effective against fungal or viral infections. This medication may be prescribed for other uses. If you have any questions, please ask your doctor or pharmacist."

Answered by AI

What kind of bacteria does neomycin treat?

"Neomycin is an effective bactericidal agent against a wide variety of bacteria, including Staphylococcus aureus, and develops resistance less readily than other agents. It is also more effective against Proteus vulgaris than is polymyxin B."

Answered by AI

Clinical Trials for Neomycin Sulfate

Image of Children's of Alabama in Birmingham, United States.

Antibiotic Duration for Infections in Children

60 - 17

All Sexes

Birmingham, AL

Infections like pneumonia, skin and soft tissue infection (also called SSTI or cellulitis), and urinary tract infections (UTI) are some of the most common reasons children get admitted to the hospital. All three of these conditions require antibiotics for treatment. Although antibiotics are needed to treat the infection and help children feel better, taking them longer than needed can negatively impact children and their families. Negative impacts include things like the burdens of taking more medications and medication side effects. There are guidelines (instructions) from expert medical organizations that suggest the number of days children need antibiotics, but they give a wide range (between 5 and 14 days). Unfortunately, these guidelines are not based on high-quality studies. National data suggests that doctors often choose on the higher end of this range when writing prescriptions for children in the hospital. Our three caregiver co-investigators, other parents of hospitalized children, doctors, other care providers, and researchers, all believe that additional study is needed to determine the best length of antibiotic treatment that weighs both the benefits and harms of antibiotics. The goal of our study is to understand if 5 total days of antibiotic treatment compared to 10 total days of antibiotic treatment is better for children who have been in the hospital for pneumonia, SSTI, or UTI. We will study this question through a randomized control trial. In other words, half of the children will receive 5-days of antibiotics and the other half will receive 10-days of antibiotics. Children in this study (and their caregivers) will not know how many days of antibiotics they will receive to cure their infection because some children will take a placebo (or a pill without antibiotics in it). Only the pharmacy will know if a child is getting antibiotic or placebo (for days 6-10 of treatment). During the first phase of the trial (feasibility phase), 4 hospitals will enroll children in the study. We plan on enrolling 50 patients during this phase. We are starting with just 4 hospitals, so our study team can create and update our study plans if needed. We will closely review information about how many patients and families agree to participate, and if they have any trouble completing any part of the study. We will also interview families to understand the choice to participate in the study, the choice not to participate in the study, and what it is like to be in the study. During the second study phase, we will enroll 1150 more patients across all 11 hospitals. Families will complete short, daily surveys until the 15th day after they started antibiotics, then a larger survey at day 15, at day 20, and at day 30. These surveys will ask about the child's symptoms and recovery from their illness, how the antibiotics are making them feel, and if they had to go back to their doctor, emergency room, or hospital. The answers to these questions will be combined to measure how well the child did, balancing feeling better and having bad effects from the antibiotics. We will use mathematical tests to determine which antibiotic duration is better for treating these illnesses. We will complete other mathematical tests to see if all children should receive the same length of antibiotics or if certain children should be prescribed shorter courses and others longer courses.

Phase 4

Waitlist Available

Drug

Children's of Alabama (+9 Sites)

Sunitha V Kaiser, MD, MSc

Image of Baylor College of Medicine in Houston, United States.

Educational Tool for Urinary Tract Infections

18+

All Sexes

Houston, TX

Urine culture is the most common microbiological test in the outpatient setting in the United States. Unfortunately, contamination during collection is prevalent and undermines test accuracy, leading to incorrect diagnosis, unnecessary treatment, wasted laboratory resources, and inflated costs. Unnecessary antibiotic treatment increases the risk of developing antimicrobial resistance, one of the most serious threats to patients and public health. The goal of this clinical trial is to test whether a bilingual (English and Spanish) educational intervention, an animated video and pictorial flyer, can reduce urine culture contamination and associated inappropriate antibiotic use in adult patients visiting safety-net primary care clinics. The main questions it aims to answer are: 1. Does providing patients with a bilingual educational intervention reduce urine culture contamination rates? 2. Does the intervention lead to fewer unnecessary urinary antibiotic prescriptions? 3. Does providing patients with a bilingual educational intervention reduce contaminated urinalyses? Researchers will compare patients randomized to receive the educational intervention (video and flyer) to those receiving usual care to see if the intervention improves urine collection accuracy and reduces inappropriate antibiotic use. Participants will watch a short, animated video with step-by-step instructions for proper midstream clean-catch urine (MSCC) collection, receive a pictorial flyer (with stills from the video) reinforcing the instructions, and provide a urine sample for culture. Hypothesis: patients who receive the educational intervention will have: lower urine culture contamination rates (primary outcome), fewer urinary antibiotic prescriptions (secondary outcome), and fewer contaminated urinalyses (secondary outcome). The objectives are to (1) develop educational tools: Create an animated video and pictorial flyer with step-by-step urine collection instructions for women and men, developed through an iterative, stakeholder-engaged process, (2) assess acceptability: Use mixed methods (quantitative surveys and qualitative interviews) to evaluate and refine the tools for usability and cultural/linguistic appropriateness, and (3) test effectiveness: Conduct a randomized controlled trial to assess the intervention's impact on urine contamination rates, antibiotic prescribing, and patient satisfaction.

Waitlist Available

Has No Placebo

Baylor College of Medicine

Larissa Grigoryan, MD, PhD